BACKGROUND: The efficacy, @entity137 , and prognostic factors of high-dose proton beam therapy (PBT) for peripheral stage I non-small-cell @entity2 were assessed in this retrospective study. MATERIALS AND METHODS: Fifty @entity1 with peripheral stage I non-small-cell @entity2 , two of whom had @entity2 , underwent high-dose PBT between January 2009 and September 2014. The relative biological effectiveness of the proton beam was defined as 1.1. The beam energy and spread-out Bragg peak were fine-tuned for the 90% isodose volume of the prescribed dosage to encompass the planning target volume. The cumulative survival curves were calculated using the Kaplan-Meier method. Treatment @entity137 were evaluated using version 4 of the Common Terminology Criteria for Adverse Events, version  4. RESULTS: The study included 35 males and 15 females with a median age of 72.5 years. The median follow-up period was 22.8 months. The clinical stage was IA in 44 (85%) and IB in eight (15%) @entity5 . The total dose of PBT was 66 GyE in 10 fractions in all @entity5 . Three-year overall survival rate among all @entity1 was 87.9% (95% confidence interval [CI], 94.8%-73.2%). Forty-five @entity1 were alive, and 5 were dead. Three-year local control and progression-free survival rates were 95.7% (95% CI, 98.9%-83.8%) and 76.3% (95% CI, 86.9%-59.3%), respectively. Only one @entity1 experienced Grade 2 @entity55 . CONCLUSION: High-dose PBT may be an effective and safe treatment option for @entity1 with stage I non-small-cell @entity2 .

Clinical Outcomes and Prognostic Factors of High-Dose Proton Beam Therapy for Peripheral Stage I Non-Small-Cell XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity2 :: ('MESH:D008175', 'Disease') :: ['heterochronic multiple lung cancers', 'lung cancer']
@entity2 :: (MESH:D008175,Disease) :: ['Lung Cancer']
